Truist lowered the firm’s price target on Tourmaline Bio (TRML) to $63 from $74 but keeps a Buy rating on the shares. The firm is also raising its FY25 EPS view to ($3.65) from ($4.45). Truist is updating its model to reflect Pacibekitug opportunity in ASCVD, atherosclerotic cardiovascular disease, which represents significant upside to the company, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Truist biotech analyst holds an analyst/industry conference call
- Tourmaline Bio’s TOUR006: Potential Best-in-Class IL-6 Treatment with Strategic Market Positioning
- Positive Buy Rating for Tourmaline Bio Driven by Promising Pacibekitug Developments and Strategic Value
- Tourmaline Bio price target raised to $43 from $42 at Wedbush
- Buy Rating for Tourmaline Bio: Potential of Pacibekitug and Upcoming CKD Data Release